欢迎分享，转载有版权, 快快登录 lingmed.net/reports 获取更多项目信息吧！
在本期的月刊中，灵麦医药和您分享以下信息：
GBI专题报告：仿制药一致性评价：竞争日趋白热化，争夺大战帷幕已开
2018年7月博谷数据分析团队对全球新药研发行业融资情况的分析
In this month summary, Lingmed recommends
GBI Report: Battle Ready: Curtain rises on new era for quality generics in China
The July Financial analysis of global bio-pharmaceuticals market by Biotechgate data analysis team
PART I
GBI专题报告：仿制药一致性评价：竞争日趋白热化，争夺大战帷幕已开
灵麦医药的公司使命之一是“向中国市场引进创新医疗产品来提高中国患者的生活质量，拯救患者的生命”。为实现这个使命，灵麦医药致力于支持中国区大型医药企业引进创新医疗产品。本月，灵麦医药独家推荐GBI的分析报告--仿制药一致性评价：竞争日趋白热化，争夺大战帷幕已开。
欲知更多项目分析报告及行业洞见，请点击文末“阅读原文”下载全文或联系我们info@lingmed.net
One of Lingmed company missions is “Bring Innovative healthcare products to China market to improve Chinese patients’ life quality and save lives.” In order to achieve this mission, currently Lingmed support big Pharma in China to identify good innovative assets to bridge the innovation into China market. This month Lingmed analyst team shares with GBI report -- Battle Ready: Curtain rises on new era for quality generics in China.
Click "read more" to download the full report or contact us for more market analysis reports via info@lingmed.net
PART II
博谷数据分析团队对全球新药研发行业融资情况的分析
The Financial analysis of global bio-pharmaceuticals market by Biotechgate data analysis team
2018年6月,生物技术治疗领域融资水平进一步下降。继2018年第一季度的高融资水平以后，第二季度显得相对平静，和我们在2017年看到的情况类似。
6月欧洲的融资轮数有所下降，但总融资额较5月上升了一倍，从1.99亿美元增长到3.94亿美元。美国的融资金额却出现每单融资金额下降的趋势，约下降了38%，总融资数也有所下降，融资总额从11.98亿美元下降到7.46亿美元。
今年6月，最大的一轮融资来自于中国的I-Mab Pharma，是中国最大的一笔C轮融资。6月第二大的一笔交易是英国的FreelineTherapeutics，而第三的交易是美国的Kaleido Biosciences。
欲知更多2018年6月医药行业融资亮点，请登录www.lingmed.cn/reports下载全文或联系我们info@lingmed.net。
In June 2018,the levels of financing for biotech therapeutic companies went down once more. After the strong first quarter of 2018, the second quarter of the year is much quieter, similar to what we have seen in 2017.
The number of financing rounds observed in the EU in June, has decreased, but with a value nearly 100% higher compared to May,increasing from 199m USD to 394m USD. The US financing saw a decline in theaverage deal value by 38%, from 1198m USD to 746m USD, with a corresponding decrease in overall financing rounds.
In June, the largest financing round was led by China-based I-Mab Pharma, closing one of the largest-ever Series C rounds inChina. The second largest deal in June was by UK-based Freeline Therapeutics,while the third largest round was led by US-based Kaleido Biosciences. Findmore details on these deals below.
Source: Biotechgate.com
The graph contains only financing rounds of private and independent biotech therapeutic and diagnostic companies. Financing amounts and number of rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.
Full report to be downloaded at www.lingmed.cn/reports or contact us info@lingmed.net
灵麦医药是以下两家情报数据库在中国的独家合作伙伴：
Biotechgate/博谷 - 全球创新药和器械产品收购和引进数据库
EvaluatePharma/预估医药 - 全球医药研发、销售、市场预估等竞争情报数据库
想要下载完整报告?
请登录 www.lingmed.cn/reports
或点击下方“阅读原文”马上下载